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Introduction
Cervical cancer is the leading cause of mortality due to a malignant neoplasm for young
women in Latin America and the leading cause of cancer among women of any age in
Nicaragua. Additionally, cervical cancer is the third most common cause of cancer death in
females worldwide. 1-4 The incidence of cervical cancer disproportionately impacts women who
come from a low socioeconomic status. This disproportional cancer rate in has been linked to
many factors including illiteracy, poverty, poor hygiene practices, smoking, low screening
coverage, decreased access to health services, underdeveloped laboratory services and lack of
education regarding HPV, cervical cancer and screening. This leads to increased mortality rates
in Latin America, the Caribbean and some parts of Africa.1, 5-6
There are about 200 different genotypes of HPV, approximately 15 of which can lead to
the development of precancerous lesions. If these precancerous lesions remain untreated, this
leads to the development of cervical cancer. Recently it has become accepted that not only is
HPV related to the development of cervical cancer, but it is a necessary factor for cancer to
develop. Therefore, cervical cancer is considered to be a cancer as a result from a sexually
transmitted infection. Thus, cervical cancer is one of few cancers that can be prevented.1-2,6-7
It is important to acknowledge this paper will focus on just the screening aspect of
prevention. There are also vaccines now available for preventing certain oncologic strains of
HPV which ultimately leads to prevention of cervical cancer. There is not yet an organized
program offering HPV vaccination in Nicaragua due to the high cost of the vaccine.8 Because of
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this, learning the most effective screening practice in Nicaragua is pertinent to decreasing the
rates of cervical cancer there.
The aim of this paper is to look for the most efficient and effective way to prevent HPV
and cervical cancer in Nicaragua.

Background
General screening and treatment options:
There are multiple strategies for cervical cancer screening that will be considered in this
paper. Two different timelines for screening include opportunistic and organized screening.
Opportunistic screening occurs when a woman is offered a Papanicolou (Pap) test when visiting
the healthcare establishment for a different health reason. Organized screening requires a
more complex system to invite all members of the at-risk population to be screened.8 While
these definitions have traditionally been used for Pap testing, they could also be applied to
other forms of screening.
There are three specific screening tests that will be considered in this paper: Pap testing,
visual inspection with acetic acid (VIA) and HVP DNA testing. Cervical cytology is assessed by
Pap testing using a speculum and lab evaluation of the cells obtained. This technique is the
most common technique used for cervical cancer detection. It is meant for early detection of
cervical cancer or its precursor lesions.1 VIA is a technique in which vinegar is applied to the
cervix turning any dysplastic epithelium white. These lesions can be seen with the naked eye
when the patient undergoes a pelvic exam. The final screening technique that will be
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considered is HPV DNA testing, specifically a test called careHPV. This test uses a swab of either
vaginal or cervical tissue to test for oncologic genotypes of HPV.1,4
If any of the above screenings are positive, a patient can then be referred for
colposcopy. This is a procedure in which the healthcare provider uses a scope to examine the
cervix and vagina, and can perform a biopsy to remove abnormal tissue to test for cancer.
Possible treatment options include loop electrosurgical excision procedure (LEEP), cryotherapy,
laser therapy or conization. These procedures remove abnormal tissue by electrical current,
freezing, narrow beam of intense light and removal with a knife, respectively.9 The goal of these
therapies is to remove any abnormal tissue before it becomes cancerous.
Pap screening in Nicaragua:
Pap screening was the first screening method implemented in Latin America beginning
in the 1960’s. When introduced to Nicaragua, it was modeled after first world countries. The
strategy includes cytology followed by colposcopy, biopsy and treatment as needed. 5,10-11 In
Nicaragua, women are opportunistically screened if determined to be in a high-risk group. This
group includes women with multiple sex partners, early age at first intercourse, high parity, low
socioeconomic status and low education level.6 While pap screening was a positive step toward
awareness of cervical cancer screening, between 1975-1990 mortality rates remained
unchanged.10
The lack of success of Pap screening in Nicaragua and other Latin American countries
has been attributed to multiple factors. First, access is a major issue for many women in
Nicaragua. Women in any socioeconomic group were more likely to receive a pap if they had a
recent healthcare visit for another reason because the screening model is opportunistic. Thus,

HPV Screening in Nicaragua

6

there is a poor coverage for screening in Nicaragua for women who do not go in for routine
healthcare visits. This differs from the first world countries this method was modeled after
because most first world countries use organized rather than opportunistic screening models.
In order for a Pap screening program to be effective, women are required to visit their
healthcare setting for multiple visits. These visits can include procedures to collect cytology
samples, colposcopy if necessary, procedures to collect biopsies, communication of results and
for treatment. Results for cytology testing take multiple days, so if follow-up is needed for a
positive screen the patient must return to the clinic. The lack of women following up after a
positive test is one of the biggest hindrances for a successful Pap screening program in
Nicaragua. Additionally, the schedule for pap screening is time consuming. The schedule
requires yearly screening for 3 years, and if those are all negative follow up every three
years.5,10
Access to all of the necessary equipment and skilled providers can be a hindrance to Pap
testing. Pap testing necessitates a means for the cervical samples to be transported to
laboratories for analysis and well-trained technicians to interpret results. In one study,
proficiency test for the cytologists interpreting Pap smears in Nicaragua showed a high baseline
rate of false negative readings and significant variation on positive rates. Even with external
quality assurance implementation, the quality of cytology could only be improved slightly, and
did not remain at a higher level of quality after intervention.10 This is not only due to the
reliance on human skills and judgement, but also on the technology itself. In Latin American
countries, the sensitivity of cervical cytology is only between 22-42%. The time and labor-
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intensive nature of pap testing is very expensive which leads to cost issues on top of the quality
issues mentioned above.7, 11
Conventional alternatives to Pap testing in Nicaragua:
Because of the difficulties in implementing a successful Pap screening program, many
other options have been considered for Nicaragua. The objective of searching alternatives is to
find a cervical cancer screening process that overcomes the technical limitations of Pap
screening, simplifies the process, decreases cost and makes it more acceptable to the women
being screened.
One way to improve cytology accuracy is to use liquid based cytology over conventional
cytology. The sensitivity is higher with liquid based cytology, which is preferable when access
to screening appointments are limited.11 While the concerns of accuracy and access are
addressed, this technique does not improve the cost concerns and maintains the same
screening intervals as a Pap test.
VIA is an additional screening method that has been considered because of the high
prevalence of HPV in Nicaragua and the limited resources necessary for this technique. In the
TATI project in Peru, when compared to cytology detecting 25% of HPV cases, VIA was able to
detect 50% of cases. This demonstrates VIA is a more sensitive test. In addition to being a more
sensitive test, VIA also gives immediate results. This leads to fewer appointments necessary to
screen and treat cervical cancer. Some downfalls to VIA include the reliance on provider skills
and judgement, lack of a standard method for training, lack of standards for quality assurance
and high cost. 11
HPV DNA testing in Nicaragua:
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The newest means to screen for cervical cancer is HPV DNA testing. There are multiple
ways in which this can be implemented. HPV DNA can be detected in both vaginal and cervical
samples, although cervical samples are more sensitive. There are two ways to collect vaginal
samples: either providers can swab the patient or the patient can self-collect the sample.
Cervical samples must be collected by a provider.2-4,7,11 The specific HPV DNA test of focus for
this paper is called careHPV. There are both vaginal and cervical collection options for careHPV.
There are many benefits to using HPV DNA screening. First and foremost, it is a very
effective screening tool. In a large trial between multiple low-income countries comparing
careHPV, VIA and Pap testing, it was shown that cervical careHPV was the most sensitive for
any stage of cervical cancer. Additionally, this trial proved cervical careHPV tests are more
specific for women with CIN3+ than the other forms of screening. Vaginal careHPV was slightly
less effective than the cervical careHPV test, but was more effective than VIA. The main
criticism for careHPV in regard to quality is its relatively low specificity overall. While it is more
specific than VIA, it is less specific than Pap testing.2-4,7
Another benefit is the ease of sample collection. This opens many opportunities for
better coverage of screening. With education regarding sample collection, samples can be selfcollected by patients or those working in healthcare other than doctors. This opens
opportunities for community outreach programs to gather samples on a larger scale for more
complete coverage of preventative screening.2,3,7
The time from collecting a sample and receiving the results is approximately three
hours. Therefore, a woman is able to be screened and can wait for the results to receive
treatment on the spot if necessary.3 Screen and treat programs will be discussed below. One
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obstacle with Pap screening has been a loss of patients to follow up. If the screening and
treatment can be done in one visit to the clinic, this could reduce the progression of HPV to
cervical cancer in the community.
Many women avoid screening for cervical cancer due to religious or cultural beliefs or
because of the invasive nature of pelvic exams. This is especially true if the only providers
available to them are men. Because of this, the vaginal option for HPV DNA testing could aid in
higher coverage of screening when women are able to collect their own samples. When
researchers asked Nicaraguan women if they preferred self or provider collection, exactly half
of the respondents preferred self-collection while the other half preferred provider collection.3
Because of the effectiveness of HPV DNA testing, the PATH Start-Up project has been
implemented in Nicaragua to provide HPV DNA screening as the standard of care for cervical
cancer screening. In Nicaragua, the first and second phases of the program have been
implemented, meaning healthcare providers have been educated and trained on the program,
and the first 10,000 women have been screened through this program to identify and address
any barriers that arise. The biggest obstacle found thus far is adequate follow up for positive
screening to confirm diagnosis and treat the patient. Multiple combinations of screening
methods were studied to solve this problem including Pap testing alone, HPV DNA testing with
cryotherapy if positive, HPV DNA with VIA if positive and HPV DNA with Pap testing if positive.
Of these options, HPV DNA testing with cryotherapy every five years was the most effective and
least costly strategy in Nicaragua. This has been termed a “screen and treat” approach. This
approach has been shown to be a very effective prevention system, reducing lifetime risk of
cervical cancer by 29.5%. Because access to cryotherapy is not always feasible in low resource
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settings, HPV DNA with VIA is the next best option when considering efficacy, cost and
accessibility. 2,4,9

Methods
For background information on HPV epidemiology, current practices for screening and
prevention and the efficacy of prevention, PubMed and Google Scholar were used. PubMed
search terms used: HPV Nicaragua; HVP vaccine Nicaragua; Cervical Cancer Screening
Nicaragua; HPV Screening Nicaragua. Google Scholar search terms used: HPV Screening
Nicaragua, HPV Nicaragua.
Once a general understanding of HPV and cervical cancer in Nicaragua was attained and
the current goals for prevention were studied, face to face interviews were completed. The
goal of the interviews was to learn practices are currently utilized for cervical cancer screening
and prevention. Additionally, education for both providers and the general community were
assessed. Furthermore, attitudes toward current practices and efficacy of cervical cancer
prevention were of interest.
Interviews were conducted with Nurse Silvia at Centro de Mujeres Acahual, Lic Alba
Sandocal at a public healthcare center, Gabriel Serrano at La Mascota Hospital, Dr. Lionel
Argüello, an epidemiologist and president of the Nicaraguan Association of General
Practitioners, Elsa Granados at a community healthcare center in La Corona rural community,
and with a nurse and patients at Casa Materna.
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Discussion
The success of cervical cancer prevention depends on both the detection and the
treatment of precancerous lesions before they become cancerous. With the various options
available for both screening and treatment, it is difficult to determine which combination of
practices will best serve the Nicaraguan population. It is important to take the lifestyle of the
Nicaraguan women and the socioeconomic status of both the individual women and the
population as a whole to determine what will be most effective in preventing the highly
prevalent disease.10
Pap testing in combination with HPV vaccination has been a successful model for first
world countries where regular access to healthcare screening is possible. According to research
conducted in Nicaragua, this model has less success in third world countries. There are multiple
factors that lead to the decreased efficacy including cost, women’s access to healthcare, access
to the tools and a laboratory for interpretation of the tests and provider skill. Due to the high
rates of cervical cancer and decreased success of Pap testing in Nicaragua, many other
screening and prevention techniques have been considered.
Through research, it has been hypothesized that using HPV DNA testing with
cryotherapy every five years would be the most effective and accessible form of prevention
available for Nicaraguan women. Currently, this is being tested through the Start Up program. If
cryotherapy is not a realistic means for the “screen and treat” approach to prevention, using
HPV DNA to screen followed by VIA for positive results has been explored as an alternative. If
implemented, only women who are positive with both screenings are referred on for treatment
at another clinical setting.
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When in Nicaragua, my goal was to observe how successful the implementation of HPV
DNA testing has been in reality and what providers opinions were of this new tool. On paper,
the cost savings and ease of testing seems to be a promising and life changing approach to
preventing cervical cancer. Not only is it a sensitive and relatively specific test, according to the
research it is cost effective, takes into account local views of modesty during sensitive exams
and can be done out of the clinic setting to increase access to screening.
I was surprised to discover through interviews that the research had overstated many
aspects to careHPV testing. Out of the 6 places visited in which cervical cancer screening was
discussed and/or performed, not one utilized careHPV or any other form of HPV DNA testing.
According to Nurse Silvia Cisneros of Centro de Mujeres Acahual on July 11, 2017, HPV DNA
testing is not utilized because of cost. She mentioned that HPV DNA tests may be done in the
private sector, but for an NGO the cost is too great. Lic Alba Sandoval who works in a
government funded public health clinic echoed a similar message on July 12, 2017. She stated
both the HPV DNA test and HPV vaccinations are too expensive for public clinics, but both of
these services could potentially be found in a private healthcare setting for individuals who can
afford to pay out of pocket. Dr. Leonel Argüello, President of the Nicaraguan Association of
General Practitioners and epidemiologist further explained this issue during an interview
conducted on July 14, 2017. He contradicted the nurses at the previous meetings and stated
there are no HPV DNA tests currently being utilized in Nicaragua, including clinics and hospitals
in the private sector. He stated that the idea for implementing careHPV has been discussed in
recent meetings he has attended, but at this point in time they are too expensive, even for the
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private sector. He explained they may be utilized in the future in private clinics, but not at this
time.
Although HPV DNA testing was not observed anywhere in Nicaragua, cervical cancer
screening and testing was taken seriously throughout all of the healthcare settings visited. Each
of the interviewees brought up the importance of cervical cancer screening without prompting.
This attention to cervical cancer was unique, as no other medical condition was deliberately
covered in all of our meetings without prompting. This speaks to the seriousness in which
cervical cancer screening and prevention is taken in Nicaragua.
Surprisingly, the equipment needed for Pap testing is available in multiple settings
ranging from a small, rural clinic in the La Corona Community to the large public health clinic in
Managua to a private clinic/ teaching facility in Cuidad Sandino. Through literature review, cost
was determined to be a deterring factor for Pap testing in Nicaragua. This proved to be false
when considering all of the settings in which the equipment was available. Nurse Silvia
Cisneros explained that the NGO she works for gets funding for cervical cancer screening
through the government, which may explain how readily available the equipment was in both
urban and rural locations.
The cervical cancer screening practices varied in each setting visited. Centro de Mujeres
Acahual, a women’s NGO organization, serves ten local communities. The healthcare promotors
there give pap smear “tickets” out in the community and at health fairs that occur two to three
times per year to increase screening rates. This location has the capability to conduct Pap tests,
biopsies, colposcopy and cryotherapy all on site. This organization handles diagnoses up to
CIN2 and refers CIN3 and in situ patients to the local hospital for treatment. The providers at
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Centro de Mujeres Acahual recommend screening yearly for negative tests, but every three to
six months for positive tests (which is more frequent than the national guidelines). The steps to
care are as follows: Pap test which is followed by a biopsy if positive. Depending on the results
of the biopsy, cryotherapy or colposcopy are used for treatment.
When visiting a large public healthcare center in Managua, patients were screened using
a Pap test. This healthcare center is associated with a specialty center funded by Iran which
had the funding for more screening and treatment options. This specialty center can only be
utilized by patients with a referral from the public healthcare center. At the specialty center,
there is a room in which an average of 20 Pap tests are done per day (figure 1). Additionally, on
Tuesdays and Thursdays, colposcopy, VIA and cone biopsies can be scheduled. When meeting
with Lic Alba Sandoval on July 12, 2017, she explained that in the first six months of 2017,
between the public healthcare center and the specialty center 5,500 Pap tests had been
completed. Of those tests, 47 patients were at a high risk for developing cancer and 8 were
already cancerous. The patients diagnosed with cancer were referred to the hospital for
treatment, including chemotherapy if needed ,and for psychological and social support.
At a private teaching hospital in Cuidad Sandino, Pap testing was again the accepted
form of cervical cancer screening. There was one room dedicated to Pap testing and another
room next door dedicated to colposcopies and VIA (figures 2 and 3). Although the equipment is
available at the clinic, providers from Germany come only four times per year perform the
screening. According to Dr. Leonel Argüello, at this location doctors are taught to treat as soon
as any cervical abnormality is found. His reasoning was because it takes 10 years for abnormal
cells infected with HPV to become cancerous, so early treatment can prevent cancer. To
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accomplish this, Pap testing is preferred. If Pap testing is unavailable, providers are taught to
utilize VIA as a backup screening method.
The findings in Nicaragua were much different than what was expected from the
literature reviewed. HPV DNA testing was not utilized in any setting. Pap testing was the
preferred screening method and VIA was also utilized in a couple settings. The main deterrent
for HPV DNA testing was the cost associated with this new screening method. That was an
interesting finding because it contradicted the literature review that pointed to Pap testing as
being too costly. Ultimately, Pap testing is relatively easy for the women of Nicaragua to access
in both the public and private sectors. Cervical cancer screening was a priority in the healthcare
settings visited.

Conclusion
Cervical cancer disproportionately effects women in low resource settings, including the
women of Nicaragua. Because of the high prevalence of cervical cancer, which is a preventable
form of cancer, more adequate screening and intervention needs to be implemented to
decrease the burden of the disease. While Pap screening at frequent intervals is an effective
method for prevention in first world countries, according to the literature, it is not the most
effective program in low resource settings like Nicaragua. According to a literature review, this
is due to cost, lack of accessibility and the low sensitivity of the test. Research has shown that
the most effective screening method in Nicaragua is HPV DNA testing with cryotherapy at 5
year intervals. If cryotherapy is too difficult to attain due to cost, HPV DNA testing with VIA is a
suggested alternative. On paper, the efficacy of HPV DNA goes beyond cost as it takes into
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account the local women’s attitudes towards pelvic exams and access to regular healthcare
services (or lack there of).
While HPV DNA testing with cryotherapy was the best practice found in the research, in
reality this was not proven to be an effective strategy for cervical cancer prevention in
Nicaragua. Due to cost and the resources available, Pap testing and VIA are the preferred
methods for screening for cervical cancer over HPV DNA testing. Many healthcare facilities also
have cryotherapy and/or the tools necessary for cone biopsy available for early intervention. If
the interventions are not available on site, there are other hospitals or clinics nearby where
patients are referred for interventions. These methods were consistently used throughout both
public and private healthcare facilities, both small and large. Currently, the consensus from
providers in is to utilize Pap testing or VIA to screen for cervical cancer and to refer any patients
they were not able to handle in house, and early detection and intervention was a priority for
providers.
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